Double-strength beclomethasone dipropionate (84 micrograms/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis.
BACKGROUND
The use of intranasally administered corticosteroid sprays is an established treatment option for seasonal allergic rhinitis.


METHODS
In this double-blind, placebo-controlled, multicenter study, 438 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated for 4 weeks with double-strength beclomethasone dipropionate (BDP) aqueous nasal spray (84 micrograms/spray: BDP-ds), once daily; regular-strength BDP (42 micrograms/spray: BDP-rs), twice daily; high-strength BDP (336 micrograms/spray: BDP-hs), once daily; or placebo. BDP-hs was included as a safety comparison group. All treatments were given as two sprays per nostril.


RESULTS
Physician-rated nasal symptom scores were significantly improved in all three active treatment groups compared with those of the placebo group within the initial 3 days of treatment. Improvement was maintained throughout the 4-week treatment period. BDP-ds and BDP-rs were equivalent at all time points. The BDP-ds, BDP-rs, and BDP-hs groups had greater numbers of patients with a good or excellent therapeutic response at end point than the placebo group. All treatments were well-tolerated, and no unexpected adverse events were reported. No effects on laboratory evaluations or vital signs were evident for any treatment group.


CONCLUSIONS
The results of this study show that BDP-ds given once a day and BDP-rs given twice a day in the same total daily dose are comparably safe and effective in the treatment of patients with seasonal allergic rhinitis.
Prenner
B M
BM
Allergy Associates Medical Group. Inc., San Diego, CA, USA.
Chervinsky
P
P
Hampel
F C
FC
Howland
W C
WC
Lawrence
M
M
Meltzer
E O
EO
Munk
Z M
ZM
Ratner
P H
PH
Seltzer
J M
JM
Settipane
G A
GA
Lorber
R R
RR
Harrison
J E
JE
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002744:Chlorpheniramine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D017060:Patient Satisfaction; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology; D012996:Solutions
D012996:Solutions; D002744:Chlorpheniramine; D001507:Beclomethasone